Connor, Clark & Lunn Investment Management (CC&L)
YMAB

Connor, Clark & Lunn Investment Management (CC&L)’s Y-mAbs Therapeutics YMAB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,084
Closed -$49.1K – 1708
2025
Q1 		$49.1K Buy
+11,084
New +$64.3K ﹤0.01% 1369
2024
Q4 		– Sell
-94,225
Closed -$1.24M – 1676
2024
Q3 		$1.24M Sell
94,225
-81,830
-46% -$1.04M 0.01% 814
2024
Q2 		$2.13M Sell
176,055
-26,019
-13% -$351K 0.01% 638
2024
Q1 		$3.29M Buy
202,074
+32,071
+19% +$432K 0.01% 527
2023
Q4 		$1.16M Sell
170,003
-13,945
-8% -$80.7K 0.01% 822
2023
Q3 		$1M Sell
183,948
-1,885
-1% -$11K 0.01% 814
2023
Q2 		$1.26M Buy
185,833
+11,719
+7% +$87.8K 0.01% 730
2023
Q1 		$872K Buy
174,114
+3,194
+2% +$13K ﹤0.01% 745
2022
Q4 		$834K Buy
170,920
+127,068
+290% +$923K ﹤0.01% 750
2022
Q3 		$632K Buy
43,852
+7,798
+22% +$129K ﹤0.01% 764
2022
Q2 		$545K Buy
36,054
+9,611
+36% +$112K ﹤0.01% 755
2022
Q1 		$314K Buy
+26,443
New +$272K ﹤0.01% 865

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s YMAB Position: Q2 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 11,084 shares — an estimated $49.1K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in YMAB in Q1 2022 and held it in 12 quarters. The position peaked at $3.29M in Q1 2024. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,084 Y-mAbs Therapeutics shares in Q2 2025, an estimated $49.1K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Y-mAbs Therapeutics in Q1 2022 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Y-mAbs Therapeutics position peaked at $3.29M in Q1 2024.
  • 97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2025, filed 7 Aug 2025.